(HQH) Tekla Healthcare Investors - Ratings and Ratios
Biotechnology, Medical Devices, Pharmaceuticals
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 12.92% |
| Yield on Cost 5y | 15.13% |
| Yield CAGR 5y | 1.79% |
| Payout Consistency | 71.3% |
| Payout Ratio | 139.1% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 19.8% |
| Value at Risk 5%th | 33.2% |
| Relative Tail Risk | 1.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.17 |
| Alpha | 15.93 |
| CAGR/Max DD | 0.66 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.431 |
| Beta | 0.611 |
| Beta Downside | 0.603 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.14% |
| Mean DD | 5.53% |
| Median DD | 4.87% |
Description: HQH Tekla Healthcare Investors December 01, 2025
Abrdn Healthcare Investors (NYSE: HQH) is a closed-ended equity fund that targets global public-equity companies in the healthcare arena-biotech, medical devices, and pharmaceuticals. The mandate emphasizes small-cap growth stocks, applying fundamental analysis that weighs market positioning, management depth, technological moat, and the ability to fund expansion either internally or via external capital.
While the fund benchmarks against the NASDAQ Biotechnology Index, the S&P 500, and the S&P 1500 Healthcare Index, its performance is heavily driven by sector-specific catalysts such as FDA approval pipelines, R&D intensity, and demographic tailwinds (e.g., a projected 1.5 % annual increase in U.S. healthcare spending through 2028). As of the latest filing, HQH reported roughly $1.2 billion in assets under management with a net expense ratio of 0.85 % and a portfolio turnover of about 45 %.
Key risks include the concentration in small-cap biotech, which can amplify volatility around clinical trial outcomes and regulatory decisions. A disconfirming signal would be a sustained rise in interest rates that compresses the valuation multiples for growth-oriented healthcare firms; such a shift would likely erode HQH’s relative performance versus broader market benchmarks.
For a deeper dive into HQH’s valuation metrics and peer comparison, you might explore the fund’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (320.0m TTM) > 0 and > 6% of Revenue (6% = 1.13m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA 0.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.42% (prev -0.53%; Δ 7.95pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 8.72m <= Net Income 320.0m (YES >=105%, WARN >=100%) |
| Net Debt (-59.0) to EBITDA (99.7m) ratio: -0.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (55.5m) change vs 12m ago 9.65% (target <= -2.0% for YES) |
| Gross Margin 72.71% (prev 90.16%; Δ -17.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.79% (prev 10.98%; Δ -9.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.45 (EBITDA TTM 99.7m / Interest Expense TTM -220.4m) >= 6 (WARN >= 3) |
Altman Z'' 32.05
| (A) 0.00 = (Total Current Assets 2.61m - Total Current Liabilities 1.21m) / Total Assets 1.10b |
| (B) 0.09 = Retained Earnings (Balance) 101.6m / Total Assets 1.10b |
| (C) 0.09 = EBIT TTM 99.7m / Avg Total Assets 1.05b |
| (D) 29.63 = Book Value of Equity 101.6m / Total Liabilities 3.43m |
| Total Rating: 32.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.75
| 1. Piotroski 3.0pt |
| 2. FCF Yield 0.81% |
| 3. FCF Margin 46.15% |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -0.00 |
| 6. ROIC - WACC (= 0.92)% |
| 7. RoE 30.74% |
| 8. Rev. Trend 31.65% |
| 9. EPS Trend -53.74% |
What is the price of HQH shares?
Over the past week, the price has changed by -1.18%, over one month by +0.95%, over three months by +4.69% and over the past year by +31.48%.
Is HQH a buy, sell or hold?
What are the forecasts/targets for the HQH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 22.6 | 17.9% |
HQH Fundamental Data Overview January 11, 2026
P/S = 142.8035
P/B = 0.9835
Revenue TTM = 18.9m USD
EBIT TTM = 99.7m USD
EBITDA TTM = 99.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -59.0 USD (from netDebt column, last fiscal year)
Enterprise Value = 1.08b USD (1.08b + (null Debt) - CCE 59.0)
Interest Coverage Ratio = -0.45 (Ebit TTM 99.7m / Interest Expense TTM -220.4m)
EV/FCF = 123.4x (Enterprise Value 1.08b / FCF TTM 8.72m)
FCF Yield = 0.81% (FCF TTM 8.72m / Enterprise Value 1.08b)
FCF Margin = 46.15% (FCF TTM 8.72m / Revenue TTM 18.9m)
Net Margin = 1695 % (Net Income TTM 320.0m / Revenue TTM 18.9m)
Gross Margin = 72.71% ((Revenue TTM 18.9m - Cost of Revenue TTM 5.15m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 0.98 (Enterprise Value 1.08b / Total Assets 1.10b)
Interest Expense / Debt = unknown (Interest Expense 48.2m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 78.7m (EBIT 99.7m * (1 - 21.00%))
Current Ratio = 2.15 (Total Current Assets 2.61m / Total Current Liabilities 1.21m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.00 (Net Debt -59.0 / EBITDA 99.7m)
Debt / FCF = -0.00 (Net Debt -59.0 / FCF TTM 8.72m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.39% (Net Income 320.0m / Total Assets 1.10b)
RoE = 30.74% (Net Income TTM 320.0m / Total Stockholder Equity 1.04b)
RoCE = 9.09% (EBIT 99.7m / Capital Employed (Total Assets 1.10b - Current Liab 1.21m))
RoIC = 9.09% (EBIT 99.7m / (Assets 1.10b - Curr.Liab 1.21m - Cash 59.0))
WACC = 8.17% (E(1.08b)/V(1.08b) * Re(8.17%) + (debt-free company))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 69.45% ; FCFF base≈8.72m ; Y1≈5.72m ; Y5≈2.61m
Fair Price DCF = 0.89 (EV 49.6m - Net Debt -59.0 = Equity 49.6m / Shares 55.5m; r=8.17% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -53.74 | EPS CAGR: -45.77% | SUE: -0.80 | # QB: 0
Revenue Correlation: 31.65 | Revenue CAGR: 15.85% | SUE: N/A | # QB: 0
Additional Sources for HQH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle